Please ensure Javascript is enabled for purposes of website accessibility

Penney Kicks Drugstore Habit

By Rich Duprey – Updated Nov 16, 2016 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The retailer has completed its sale of Eckerd Drugs to focus on selling clothes.

Just say no.

After a 35-year run in the business, venerable retailer J.C. Penney (NYSE:JCP) has decided selling clothes, not drugs, is what ultimately made it "venerable." It completed the sale of its Eckerd drugstore operations to CVS (NYSE:CVS) and the Jean Coutu Group for $4.5 billion.

It's not difficult to see that a clothing store operating a huge chain of drugstores is a classic example of Peter Lynch's concept of "di-worse-ification" -- that is, diversification so far removed from one's core competency as to weaken the corporation practicing it.

Although most don't realize it, J.C. Penney has had a long history of owning drugstores, beginning in 1969 when it acquired Thrift Drugs. The synergies of no-go growth in department stores with go-go consolidation in discount drugstores in the mid-1990s had Penney on a buying binge, acquiring 200 Rite Aid (NYSE:RAD) stores, the Fay Drugs chain, Eckerd, and Genovese Drugs. It quickly became the No. 3 drugstore chain behind CVS and Walgreen (NYSE:WAG).

Yet too much of a good thing is too much of a good thing. Even as the competition reported rising sales and earnings, Penney was hard-pressed to keep up. And not just with other drugstore chains but also with discounters such as Wal-Mart (NYSE:WMT) and Target (NYSE:TGT), which were able to filter off sales for important front-end items even as pharmacy-related sales grew.

CEO Alan Questrom is in Year Four of a five-year rehab plan. The turnaround specialist said the company will use the proceeds from the sale of Eckerd to pay down $2.3 billion of its $5.1 billion long-term debt while at the same time buying back $3 billion worth of company stock, a move that could reduce its diluted share count by 23%. Those measures, coupled with the elimination of $3.4 billion in lease obligations related to Eckerd, would create an $8 billion improvement in its balance sheet.

It's a move the credit rating agencies have looked upon favorably. Last month, both Moody's (NYSE:MCO) and Fitch Ratings put J.C. Penney on notice for a possible upgrade.

It's been a long, strange trip for the 100-year-old retailer. Sales and profits have improved significantly over the past year as it emerges from its drugstore-induced haze. Yet di-worse-ification, like drug addiction, is something that's easy to fall back into. While investors can and should enjoy Penney's current clear-eyed plans, they ought to keep a watchful eye out for any relapse.

Fool contributor Rich Duprey has been known to enjoy a Coors Light-induced haze. He does not own any of the stocks mentioned in this article.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walmart Stock Quote
Walmart
WMT
$131.31 (0.96%) $1.25
Target Corporation Stock Quote
Target Corporation
TGT
$148.71 (-2.56%) $-3.90
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$97.74 (-0.62%) $0.61
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.69 (-0.43%) $0.14
J. C. Penney Company, Inc. Stock Quote
J. C. Penney Company, Inc.
JCPN.Q
Moody's Corporation Stock Quote
Moody's Corporation
MCO
$250.32 (-1.72%) $-4.37
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$6.50 (-7.28%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.